Where does Trevi Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$45.61M+3.7%	-$42.76M+10.8%	-$45.86M-3.5%	-$47.3M-22.0%	-$47.35M-41.1%
Depreciation and amortization	$141K-5.4%	$144K-2.0%	$151K+4.9%	$149K+4.2%	$149K+7.2%
Stock-based compensation	$6.17M+51.4%	$5.19M+44.5%	$4.75M+48.2%	$4.33M+48.6%	$4.07M+75.8%
Change in accounts payable	——	——	——	——	-$682K—
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	$1.64M+160%	$784K+153%	-$1.55M-202%
Non-cash operating lease expense	$430K-4.9%	$437K-5.0%	$528K+38.9%	$449K-4.5%	$452K—
Net cash from operating activities	-$45.3M-9.8%	-$42.09M-10.0%	-$44.01M-25.5%	-$42.68M-30.2%	-$41.27M-21.4%
Capital expenditures	——	——	——	——	——
Proceeds from maturities/sales of investments	$84.52M+16.8%	$76.57M-0.5%	$74.11M+6.7%	$74.14M+11.1%	$72.39M-1.7%
Net cash from investing activities	-$67.19M—	-$94.11M—	-$87.37M—	-$28.77M—	——
Proceeds from issuance of common stock	$1.58M+42.9%	$2.08M+428%	$1.87M+389%	$907K+309%	$1.11M+6,825%
Payments for finance leases	——	$11K-91.3%	$42K-67.2%	$74K-42.2%	$106K-17.2%
Net cash from financing activities	$112.53M+60.3%	$121.01M+96.8%	$172.2M+1,628%	$175.55M—	$70.22M—
Net increase (decrease) in cash	$38K-99.3%	-$15.18M-993%	$40.82M+512%	$104.1M+13,293%	$5.56M+158%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.67M+21.2%	$1.64M+19.8%	$1.37M-3.4%	$1.43M-7.3%	$1.38M-24.7%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$1.64M+160%	$784K+153%	-$1.55M-202%
Operating lease right-of-use asset amortization	$430K-4.9%	$437K-5.0%	$528K+38.9%	$449K-4.5%	$452K—
Write Off Of Deferred Offering Costs	——	$26K—	——	——	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$84.52M+16.8%	$76.57M-0.5%	$74.11M+6.7%	$74.14M+11.1%	$72.39M-1.7%
Finance Lease, Principal Payments	——	$11K-91.3%	$42K-67.2%	$74K-42.2%	$106K-17.2%
Payments Of Stock Issuance Costs	——	$809K—	——	——	——
Proceeds From Offering Net Of Commissions	——	$108.15M+130%	$92.87M—	$77.58M—	$62.29M—
Proceeds From Warrant Exercises	——	——	——	——	——
Offering Costs Included In Accrued Expenses	——	——	——	——	——
Free cash flow	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Trevi Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.